Vitamin D may slow progression of low-grade prostate tumors
the ONA take:
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery, new research presented at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver, Colorado has shown.
For the randomized, controlled clinical trial, researchers assigned 37 men with low-grade prostate cancer undergoing elective prostatectomies to receive either 4,000U of vitamin D daily or placebo during the 60-day waiting period prior to surgery. The patients' prostate glands were then removed and examined.
Results showed that men who received vitamin D showed improvements in their prostate tumors while those in the placebo group experienced no changes or their tumors got worse.
The findings suggest that vitamin D supplementation, well below pharmacological levels, may improve less aggressive prostate cancer by decreasing inflammation. It is not clear yet whether vitamin D prevents or treats prostate cancer, but it can prevent lower-grade tumors from becoming aggressive.
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|